Literature DB >> 32549639

Creating Catholic Regenerative Medicine Organizations in a Secular Biotechnology Field: A Physician-Scientist Experience.

Alan Moy1,2.   

Abstract

One aspect of the progressive secularization of biotechnology is the use of the by-products from abortion and the use of human embryos. These morally illicit cells and tissue create a significant moral and economic challenge for Catholics at different stages of their career. A practicing Catholic physician or scientific professional will face the dilemma of how to reconcile their Catholic identity with their profession. While the Catechism is clear on what actions Catholics should not pursue, there has been less religious guidance on what activities Catholics should proactively pursue in their professional life to advance the Catholic culture. This essay will examine these themes through the lens of a true story of the author's experience in starting Catholic for-profit and nonprofit biotechnology organizations.
SUMMARY: Abortion and the destruction of human embryos create a moral dilemma for Catholics at different stages of a physician or scientist's career. A practicing Catholic physician or scientist must reconcile their Catholic identity with their profession. While there is little professional guidance on how to advance the culture, Jesus says that one must take up the cross and direct their God-given gifts towards His name. The only way to succeed and thrive in a secular healthcare environment is to emulate Jesus by putting aside their own self-interest; pray for courage against ridicule; accept risk; and pursue scientific and medical excellence. © Catholic Medical Association 2019.

Entities:  

Keywords:  Bioethics; Catholic identity in health care; Difficult moral questions; Faith and science; Personal and professional coaching; Stem cells; Vaccines

Year:  2019        PMID: 32549639      PMCID: PMC7273632          DOI: 10.1177/0024363919890941

Source DB:  PubMed          Journal:  Linacre Q        ISSN: 0024-3639


  14 in total

Review 1.  Embryonic stem cells in drug discovery.

Authors:  John McNeish
Journal:  Nat Rev Drug Discov       Date:  2004-01       Impact factor: 84.694

2.  California dreaming? A new start for regenerative medicine in the Golden State. Interview with Dr. Zach Hall.

Authors:  Zach W Hall
Journal:  Regen Med       Date:  2007-01       Impact factor: 3.806

3.  Virus-free and oncogene-free induced pluripotent stem cell reprogramming in cord blood and peripheral blood in patients with lung disease.

Authors:  Anant Kamath; Sara Ternes; Stephen McGowan; Alan B Moy
Journal:  Regen Med       Date:  2018-11-29       Impact factor: 3.806

4.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

Review 5.  Gene therapy clinical trials worldwide to 2017: An update.

Authors:  Samantha L Ginn; Anais K Amaya; Ian E Alexander; Michael Edelstein; Mohammad R Abedi
Journal:  J Gene Med       Date:  2018-04-19       Impact factor: 4.565

6.  The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

Authors:  M G Pau; C Ophorst; M H Koldijk; G Schouten; M Mehtali; F Uytdehaag
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

Review 7.  Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.

Authors:  Michael F Naso; Brian Tomkowicz; William L Perry; William R Strohl
Journal:  BioDrugs       Date:  2017-08       Impact factor: 5.807

8.  Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration.

Authors:  Manjit S Mehat; Venki Sundaram; Caterina Ripamonti; Anthony G Robson; Alexander J Smith; Shyamanga Borooah; Martha Robinson; Adam N Rosenthal; William Innes; Richard G Weleber; Richard W J Lee; Michael Crossland; Gary S Rubin; Baljean Dhillon; David H W Steel; Eddy Anglade; Robert P Lanza; Robin R Ali; Michel Michaelides; James W B Bainbridge
Journal:  Ophthalmology       Date:  2018-06-05       Impact factor: 12.079

9.  Results from Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long-Term Outcome.

Authors:  Letizia Mazzini; Maurizio Gelati; Daniela Celeste Profico; Gianni Sorarù; Daniela Ferrari; Massimiliano Copetti; Gianmarco Muzi; Claudia Ricciolini; Sandro Carletti; Cesare Giorgi; Cristina Spera; Domenico Frondizi; Stefano Masiero; Alessandro Stecco; Carlo Cisari; Enrica Bersano; Fabiola De Marchi; Maria Francesca Sarnelli; Giorgia Querin; Roberto Cantello; Francesco Petruzzelli; Annamaria Maglione; Cristina Zalfa; Elena Binda; Alberto Visioli; Domenico Trombetta; Barbara Torres; Laura Bernardini; Alessandra Gaiani; Maurilio Massara; Silvia Paolucci; Nicholas M Boulis; Angelo L Vescovi
Journal:  Stem Cells Transl Med       Date:  2019-05-18       Impact factor: 6.940

Review 10.  Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.

Authors:  Jennifer Dumont; Don Euwart; Baisong Mei; Scott Estes; Rashmi Kshirsagar
Journal:  Crit Rev Biotechnol       Date:  2015-09-18       Impact factor: 8.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.